Houston, TX - A new study led by researchers at The University of Texas MD Anderson Cancer has shed light on the mechanisms driving metastasis in renal cell carcinoma (RCC). The team engineered an innovative model of aggressive RCC using CRISPR/Cas9 gene editing, uncovering molecular targets and genomic events responsible for chromosomal instability and metastatic progression. These findings, published in Nature Cancer, offer valuable insights for predicting metastatic potential and developing more effective therapeutic strategies.
Renal cell carcinoma is the most prevalent form of kidney cancer, and while surgery, targeted therapy, and immunotherapy have shown efficacy, a significant portion of patients experience aggressive disease progression. To better understand the underlying mechanisms driving metastasis, the researchers sought to replicate the early stages of human cancers and observe tumor evolution.
Dr. Giannicola Genovese, a professor of Genitourinary Medical Oncology, stated, "Until now, there haven't been effective experimental models for metastatic renal cancer progression, but we introduced specific mutations that closely mimic the early stages of human cancers to see how tumors evolve and metastasize." These engineered tumors exhibited significant genomic instability and a tendency to lose genetic material at the site where interferon receptor (IFNR) genes are located, enabling them to tolerate chromosomal instability.
Chromosomal instability is a hallmark of cancer associated with therapy resistance and poor prognosis. However, it remains unclear how specific chromosomal abnormalities contribute to metastasis and how tumors manage to tolerate them. By using CRISPR/Cas9-based genome editing, the researchers created RCC models lacking common tumor suppressor genes and introduced mutations in cell cycle regulator genes to replicate chromosomal abnormalities observed in metastatic RCC. Remarkably, this is the first immunocompetent somatic mosaic model for metastatic RCC, allowing the study of uncontrolled cell growth while maintaining a functional immune system.
The team performed genome sequencing and single-cell RNA sequencing on these models, leading to the identification of molecular drivers of RCC and a novel understanding of chromosomal instability's evolution. Single-cell analyses unveiled the suppression of a highly conserved cluster of IFNR genes in the model, which is known to act as critical tumor suppressors in renal cancer progression. These genes, typically involved in the immune response, demonstrated an inverse correlation with aneuploidy, an abnormal chromosomal number condition.
The study suggests that tumors adapt to high levels of chromosomal instability by disrupting the IFNR pathway, which could serve as a major biomarker for metastatic potential. Additionally, the research highlighted the evolutionary patterns shared by renal cancers in different species, converging around chromosomal instability and potentially explaining the heterogeneity of these tumors.
Moving forward, the researchers plan to test drug combinations using their newly generated models to explore tumor adaptation to various therapies. Ultimately, they aim to translate these findings into clinical trials, providing clinicians with a better understanding of treatment responses and aiding in the prediction of patient outcomes for RCC. The novel insights gained from this study pave the way for improved strategies to combat metastatic kidney cancer and offer hope for patients seeking effective treatments.
Renal cell carcinoma is the most prevalent form of kidney cancer, and while surgery, targeted therapy, and immunotherapy have shown efficacy, a significant portion of patients experience aggressive disease progression. To better understand the underlying mechanisms driving metastasis, the researchers sought to replicate the early stages of human cancers and observe tumor evolution.
Dr. Giannicola Genovese, a professor of Genitourinary Medical Oncology, stated, "Until now, there haven't been effective experimental models for metastatic renal cancer progression, but we introduced specific mutations that closely mimic the early stages of human cancers to see how tumors evolve and metastasize." These engineered tumors exhibited significant genomic instability and a tendency to lose genetic material at the site where interferon receptor (IFNR) genes are located, enabling them to tolerate chromosomal instability.
Chromosomal instability is a hallmark of cancer associated with therapy resistance and poor prognosis. However, it remains unclear how specific chromosomal abnormalities contribute to metastasis and how tumors manage to tolerate them. By using CRISPR/Cas9-based genome editing, the researchers created RCC models lacking common tumor suppressor genes and introduced mutations in cell cycle regulator genes to replicate chromosomal abnormalities observed in metastatic RCC. Remarkably, this is the first immunocompetent somatic mosaic model for metastatic RCC, allowing the study of uncontrolled cell growth while maintaining a functional immune system.
The team performed genome sequencing and single-cell RNA sequencing on these models, leading to the identification of molecular drivers of RCC and a novel understanding of chromosomal instability's evolution. Single-cell analyses unveiled the suppression of a highly conserved cluster of IFNR genes in the model, which is known to act as critical tumor suppressors in renal cancer progression. These genes, typically involved in the immune response, demonstrated an inverse correlation with aneuploidy, an abnormal chromosomal number condition.
The study suggests that tumors adapt to high levels of chromosomal instability by disrupting the IFNR pathway, which could serve as a major biomarker for metastatic potential. Additionally, the research highlighted the evolutionary patterns shared by renal cancers in different species, converging around chromosomal instability and potentially explaining the heterogeneity of these tumors.
Moving forward, the researchers plan to test drug combinations using their newly generated models to explore tumor adaptation to various therapies. Ultimately, they aim to translate these findings into clinical trials, providing clinicians with a better understanding of treatment responses and aiding in the prediction of patient outcomes for RCC. The novel insights gained from this study pave the way for improved strategies to combat metastatic kidney cancer and offer hope for patients seeking effective treatments.